Mei's group integrates techniques from molecular biology, cell biology, structure biology, protein engineering, and yeast genetics to conduct research centered on new drug development. The group’s work focuses on three main areas:

1. Discovery of novel drug targets:
   By leveraging cell biology and structural biology approaches, we investigate the function and regulatory mechanisms of potential disease-related targets, aiming to identify new drug targets and novel druggable sites.

2. Development of biologic macromolecule-based drugs:
   We have established a comprehensive nanobody development platform, which is employed to design innovative targeted therapeutics against key disease-related targets.

3. Biosynthesis of natural product-based drugs and drug precursors:
   Using structural biology and protein engineering, we conduct rational engineering of key biosynthetic enzymes involved in the production of important natural products, improving their catalytic efficiency and stability. These optimized enzymes are then integrated into microbial cell factories such as yeast to enhance the biosynthetic efficiency of the target compounds.